Ginkgo Bioworks CFO Transition Effective May 30
Slice of Healthcare Team
May 23, 2025
Key highlights
- Mark Dmytruk to resign as CFO on May 30, 2025
- Steven Coen, current Chief Accounting Officer, named successor
- Coen brings over 30 years of finance leadership experience
- Transition supports Ginkgo’s 2026 Adjusted EBITDA breakeven goal
Notable Quotes
“ We thank Mark for his dedicated service to the Company and his leadership of the finance team through many transformational phases at Ginkgo and wish him well in his next opportunity. ”
Jason Kelly, Co-founder and CEO at Ginkgo Bioworks
“ I am deeply grateful for the opportunity to have contributed to Ginkgo's mission of making biology easier to engineer, and I have full confidence in Steve and the finance team to continue driving the Company's financial vision forward. ”
Mark Dmytruk, Chief Financial Officer at Ginkgo Bioworks
“ Mark has built a high-performing finance organization and laid the groundwork for Ginkgo to continue driving toward our cost reduction targets and our goal of reaching Adjusted EBITDA breakeven by the end of 2026. ”
Steven Coen, Incoming Chief Financial Officer at Ginkgo Bioworks
Why This Matters
This leadership transition at Ginkgo Bioworks reflects the company's strategic focus on financial discipline and continuity as it pursues ambitious goals, including achieving Adjusted EBITDA breakeven by 2026. The promotion of Steven Coen, a seasoned finance executive with significant industry experience, underscores Ginkgo’s commitment to maintaining operational excellence and advancing its mission in cell programming and biosecurity.
